MPH MD - Inari Medical Chief LimFlow
| NARI Stock | USD 49.75 0.75 1.53% |
Executive
MPH MD is Chief LimFlow of Inari Medical
| Address | 6001 Oak Canyon, Irvine, CA, United States, 92618 |
| Phone | 877 923 4747 |
| Web | https://www.inarimedical.com |
Inari Medical Management Efficiency
The company has return on total asset (ROA) of (0.0321) % which means that it has lost $0.0321 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1772) %, meaning that it created substantial loss on money invested by shareholders. Inari Medical's management efficiency ratios could be used to measure how well Inari Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.0056. The current Return On Capital Employed is estimated to decrease to -0.02. As of now, Inari Medical's Non Currrent Assets Other are increasing as compared to previous years. The Inari Medical's current Other Assets is estimated to increase to about 949.3 K, while Other Current Assets are projected to decrease to under 6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Doug Wallace | Legend Biotech Corp | N/A | |
| Alfred Ford | Axonics Modulation Technologies | 53 | |
| Neil Bhalodkar | Axonics Modulation Technologies | N/A | |
| Marc Nash | Outset Medical | 35 | |
| Alan Kick | Legend Biotech Corp | N/A | |
| Arielle Bogorad | Progyny | N/A | |
| John JD | Outset Medical | 50 | |
| Mark CPA | Progyny | 58 | |
| Steven Gavel | Legend Biotech Corp | N/A | |
| Aaron Pettit | Axonics Modulation Technologies | N/A | |
| John Brottem | Outset Medical | 49 | |
| Katie Higgins | Progyny | N/A | |
| Allison Swartz | Progyny | 34 | |
| Mark MS | Outset Medical | 67 | |
| Risa Fisher | Progyny | N/A | |
| Kari Keese | Axonics Modulation Technologies | 39 | |
| Guowei Fang | Legend Biotech Corp | N/A | |
| James Hart | Progyny | N/A | |
| Tim Roberts | Legend Biotech Corp | N/A | |
| Liz Gosen | Legend Biotech Corp | N/A | |
| Danny Dearen | Axonics Modulation Technologies | 61 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0321 |
Inari Medical Leadership Team
Elected by the shareholders, the Inari Medical's board of directors comprises two types of representatives: Inari Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inari. The board's role is to monitor Inari Medical's management team and ensure that shareholders' interests are well served. Inari Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inari Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Angela JD, General Secretary | ||
| Tara Dunn, Senior Development | ||
| John Borrell, Senior Sales | ||
| Kevin Strange, Accounting, Finance | ||
| Janet Byk, VP Accounting | ||
| John CFA, Vice Relations | ||
| Tim Benner, Senior Sales | ||
| Eric Khairy, Senior Marketing | ||
| Angela Ahmad, General Secretary | ||
| Dena Truelove, VP HR | ||
| Paul Koehn, Senior Operations | ||
| William Hoffman, Pres CEO | ||
| Brian Strauss, Senior Engineering | ||
| Andrew Hykes, Chief Officer | ||
| Mitchell Hill, Chief Officer | ||
| Thomas MD, Chief Officer | ||
| MPH MD, Chief LimFlow |
Inari Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inari Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0321 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 2.79 B | ||||
| Shares Outstanding | 58.54 M | ||||
| Shares Owned By Insiders | 8.75 % | ||||
| Shares Owned By Institutions | 95.40 % | ||||
| Number Of Shares Shorted | 3.69 M | ||||
| Price To Earning | 275.35 X |
Currently Active Assets on Macroaxis
When determining whether Inari Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inari Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inari Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inari Medical Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Inari Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Inari Stock please use our How to Invest in Inari Medical guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inari Medical. If investors know Inari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inari Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.84) | Earnings Share (1.35) | Revenue Per Share 9.901 | Quarterly Revenue Growth 0.214 | Return On Assets (0.03) |
The market value of Inari Medical is measured differently than its book value, which is the value of Inari that is recorded on the company's balance sheet. Investors also form their own opinion of Inari Medical's value that differs from its market value or its book value, called intrinsic value, which is Inari Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inari Medical's market value can be influenced by many factors that don't directly affect Inari Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inari Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inari Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inari Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.